An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

Phase 3 Completed 110 enrolled Alcon Research

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to assess safety and efficacy of long-term use of AL-4943A (Olopatadine Hydrochloride Ophthalmic Solution, 0.2%) in patients with allergic conjunctivitis.

Timeline

Start: 2010-02
Primary completion: 2010-05
Completion: 2010-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olopatadine	Other / unclassified	0.2 %	Other

An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis

Summary

Timeline

Drugs

Indications